# EDGAR Filing Document

**Accession Number:** 0001653262
**File Stem:** 0001493152-26-008880
**Filing Date:** 2026-3
**Character Count:** 15557
**Document Hash:** 1405d01442ef3a9dd26d07bc12efdf96
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-008880.hdr.sgml**: 20260304

**ACCESSION NUMBER**: 0001493152-26-008880

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260304

**DATE AS OF CHANGE**: 20260304

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Akari Therapeutics Plc
- **CENTRAL INDEX KEY:** 0001541157
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981034922
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-87614
- **FILM NUMBER:** 26722344

**BUSINESS ADDRESS:**
- **STREET 1:** 401 EAST JACKSON STREET
- **STREET 2:** SUITE 3300
- **CITY:** TAMPA
- **STATE:** FL
- **ZIP:** 33602
- **BUSINESS PHONE:** (929) 274-7510

**MAIL ADDRESS:**
- **STREET 1:** 401 EAST JACKSON STREET
- **STREET 2:** SUITE 3300
- **CITY:** TAMPA
- **STATE:** FL
- **ZIP:** 33602

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Celsus Therapeutics Plc.
- **DATE OF NAME CHANGE:** 20130621

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Morria Biopharmaceuticals PLC
- **DATE OF NAME CHANGE:** 20120201
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Prudo-Chlebosz Raymond
- **CENTRAL INDEX KEY:** 0001653262

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 71 SHEPHERDS HILL
- **CITY:** LONDON
- **PROVINCE COUNTRY:** X0

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Prudo Ray
- **DATE OF NAME CHANGE:** 20150916

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 10)**

**Akari Therapeutics Plc**

*(Name of Issuer)*

**Ordinary Shares, $0.000000005 par value**

*(Title of Class of Securities)*

**00972G207**

*(CUSIP Number)*

**Win Rutherfurd, Esq.**<br>Greenberg Traurig, LLP<br>One Vanderbilt Avenue<br>New York NY 10017<br>(212) 801-9200

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**03/02/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **00972G207** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Ray Prudo, M.D.** | Name of reporting person<br>**Ray Prudo, M.D.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**ISRAEL** | Citizenship or place of organization<br>**ISRAEL** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**7551850267.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**839476200.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**7551850267.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**839476200.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**8391326467.00** | Aggregate amount beneficially owned by each reporting person<br>**8391326467.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[x] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[x] | |
| 13 | Percent of class represented by amount in Row (11)<br>**8.9%** | Percent of class represented by amount in Row (11)<br>**8.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** 1) Comprised of the Registrant's ordinary shares, $0.000000005 par value per share ("Ordinary Shares"), represented by American Depositary Shares ("ADSs"). Each ADS represents 2,000 Ordinary Shares.

2) Includes (i) 5,163,920,600 shares held of record by Reporting Person, (ii) 377,291,667 shares underlying options exercisable within 60 days of March 1, 2026 granted to Reporting Person, (iii) 2,010,638,000 shares underlying prefunded warrants exercisable within 60 days of March 1, 2026 (iii) 800,766,600 shares held of record by RPC Pharma Limited ("RPC") and (iv) 38,709,600 ordinary shares held of record by Praxis Trustees Limited as trustee of The Sonic Healthcare Holding Company ("Praxis"). Excludes up to 5,721,437,500 shares underlying warrants exercisable within 60 days of March 1, 2026 issued to Reporting Person which are subject to a 9.99% beneficial ownership limitation and with respect to which Reporting Person disclaims beneficial ownership to the extent that any exercise of such warrants would exceed such percentage. Reporting Person controls the voting and investment decisions with respect to the shares held of record by RPC and Praxis and thereby may be deemed the beneficial owner of such shares.

3) The percentage of ownership is based on 91,567,009,533 ordinary shares issued and outstanding on March 1, 2026, as per information provided to the Reporting Person by the Issuer.

| **CUSIP No.** | **00972G207** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**RPC Pharma Limited** | Name of reporting person<br>**RPC Pharma Limited** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**O1** | Citizenship or place of organization<br>**O1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**800766600.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**800766600.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**800766600.00** | Aggregate amount beneficially owned by each reporting person<br>**800766600.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.87%** | Percent of class represented by amount in Row (11)<br>**0.87%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Comment for Reporting Person:** 1) Comprised of the Registrant's ordinary shares, $0.000000005 par value per share ("Ordinary Shares"), represented by American Depositary Shares ("ADSs"). Each ADS represents 2,000 Ordinary Shares.

2) Includes 800,766,600 shares held of record by RPC. Reporting Person controls the voting and investment decisions with respect to the shares held of record by RPC and thereby may be deemed the beneficial owner of such shares.

3) The percentage of ownership is based on 91,567,009,533 ordinary shares issued and outstanding on March 1, 2026, as per information provided to the Reporting Person by the Issuer.

| **CUSIP No.** | **00972G207** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Praxis Trustees Limited as trustee of the Sonic Healthcare Holding Company** | Name of reporting person<br>**Praxis Trustees Limited as trustee of the Sonic Healthcare Holding Company** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**Y7** | Citizenship or place of organization<br>**Y7** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**38709600.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**38709600.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**38709600.00** | Aggregate amount beneficially owned by each reporting person<br>**38709600.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.042%** | Percent of class represented by amount in Row (11)<br>**0.042%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** 1) Comprised of the Registrant's ordinary shares, $0.000000005 par value per share ("Ordinary Shares"), represented by American Depositary Shares ("ADSs"). Each ADS represents 2,000 Ordinary Shares.

2) Includes 38,709,600 ordinary shares held of record by Praxis. Reporting Person controls the voting and investment decisions with respect to the shares held of record by Praxis and thereby may be deemed the beneficial owner of such shares.

3) The percentage of ownership is based on 91,567,009,533 ordinary shares issued and outstanding on March 1, 2026, as per information provided to the Reporting Person by the Issuer.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Ordinary Shares, $0.000000005 par value

**(b) Name of Issuer:**
Akari Therapeutics Plc

**(c) Address of Issuer's Principal Executive Offices:**
401 East Jackson Street, Suite 3300, Tampa, FL, 33602

This Amendment No. 10 to Schedule 13D ("Amendment No. 10") amends and supplements where indicated the Statement on Schedule 13D originally filed with the Securities and Exchange Commission on September 29, 2015 and amended on October 26, 2017, March 30, 2020, October 18, 2021, January 14, 2022, April 14, 2023, October 20, 2023, January 4, 2024, June 20, 2024 and February 14, 2025, respectively (collectively, the "Prior Schedule 13D") by and on behalf of RPC Pharma Limited, a Maltese corporation ("RPC"), Ray Prudo, M.D., a citizen of Canada ("Dr. Prudo") and Praxis Trustees Limited As trustee of The Sonic Healthcare Holding Company ("Praxis," and together with RPC, and Dr. Prudo, the "Reporting Persons"), and relates to the ordinary shares, $0.000000005 par value ("Ordinary Shares") of Akari Therapeutics, Plc, a public limited company formed under the laws of England and Wales (the "Issuer"). The Issuer's American Depositary Shares, each representing 2,000 Ordinary Shares (the "ADSs"), have been registered on a registration statement on Form F-6 (File No. 333-185197), as supplemented (File Nos. 333-234213, 333-262049 and 333-185197), and trade on the Nasdaq Capital Market under the symbol "AKTX." Capitalized terms used herein but not defined herein shall have the meanings ascribed to them in the Prior Schedule 13D. This Amendment No. 10 amends and supplements the Prior Schedule 13D as specifically set forth herein. Except as set forth below, all previous Items in the Prior Schedule 13D remain unchanged. This Amendment No. 10 is being filed to amend Items 3, 4 and 5 as set forth below and to update the number of shares of Ordinary Shares beneficially held by the Reporting Persons as a result of the transaction described below.

**Item 4. Purpose of Transaction**

On December 17, 2025, Dr. Prudo purchased the securities described in the transactions as described in Item 3 above.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Dr. Prudo, either in his individual capacity or as sole manager and member of RPC and Praxis, respectively, beneficially owns an aggregate of (i) 5,163,920,600 shares held of record by Dr. Prudo, (ii) 377,291,667 shares underlying options exercisable within 60 days of March 1, 2026 granted to Dr. Prudo, (iii) 2,010,638,000 shares underlying prefunded warrants exercisable within 60 days of March 1, 2026 (iii) 800,766,600 shares held of record by RPC and (iv) 38,709,600 ordinary shares held of record by Praxis. Excludes up to 5,721,437,500 shares underlying warrants exercisable within 60 days of March 1, 2026 issued to Reporting Person which are subject to a 9.99% beneficial ownership limitation and with respect to which Reporting Person disclaims beneficial ownership to the extent that any exercise of such warrants would exceed such percentage. Reporting Person controls the voting and investment decisions with respect to the shares held of record by RPC and Praxis and thereby may be deemed the beneficial owner of such shares.

**(b)**
See Rows 7 through 11 of cover page for Reporting Persons.

**(c)**
None of the Reporting Persons has effected any transactions in Ordinary Shares during the 60 days prior to the filing of this Amendment No. 10.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Ray Prudo, M.D.

**Signature:** /s/ Ray Prudo, M.D.

**Name/Title:** Ray Prudo, Reporting Person

**Date:** 03/04/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** RPC Pharma Limited

**Signature:** /s/ Ray Prudo, M.D.

**Name/Title:** Ray Prudo, Reporting Person

**Date:** 03/04/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Praxis Trustees Limited as trustee of the Sonic Healthcare Holding Company

**Signature:** /s/ Jodie Travers

**Name/Title:** Director for and on behalf of Praxis Trustees Limited

**Date:** 03/04/2026